Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
2006-03-28
2006-03-28
Minnifield, N. M. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C424S184100, C424S277100, C424S193100, C424S194100, C424S244100, C424S249100, C424S250100, C530S333000, C530S350000, C530S395000, C530S402000, C530S807000, C530S810000
Reexamination Certificate
active
07018637
ABSTRACT:
Multivalent immunogenic molecules comprise a carrier molecule containing at least one functional T-cell epitope and multiple different carbohydrate fragments each linker to the carrier molecule and each containing at least one functional B-cell epitope. The carrier molecule inputs enhanced immunogenicity to the multiple carbohydrate fragments. The carbohydrate fragments may be capsular oligosaccharide fragments fromStreptococcus pneumoniae, which may be serotypes 1, 4, 5, 6B, 9V, 14, 18C, 19F or 23F, orNeisseria meningitidis, which may be serotype A, B, C, W-135 or Y. Such oligosaccharide fragments may be sized from 2 to 5 kDa. Alternatively, the carbohydrate fragments may be fragments of carbohydrate-based tumor antigens, such as Globo H, LeYor STn. The multivalent molecules may be produced by random conjugation or site-directed conjugation of the carbohydrate fragments to the carrier molecule. The multivalent molecules may be employed in vaccines or in the generation of antibodies for diagnostic application.
REFERENCES:
patent: 5041516 (1991-08-01), Frechet et al.
patent: 5229490 (1993-07-01), Tam
patent: 5306492 (1994-04-01), Porro et al.
patent: 5370872 (1994-12-01), Cryz et al.
patent: 5371197 (1994-12-01), Marburg et al.
patent: 5567411 (1996-10-01), Keana et al.
patent: 5585100 (1996-12-01), Mond et al.
patent: 5623057 (1997-04-01), Marburg et al.
patent: 5795580 (1998-08-01), Jennings et al.
patent: 5807553 (1998-09-01), Malcolm
patent: 5843461 (1998-12-01), Jennings et al.
patent: 5847112 (1998-12-01), Kniskern et al.
patent: 5882645 (1999-03-01), Toth et al.
patent: 5955079 (1999-09-01), Mond et al.
patent: 5965544 (1999-10-01), Renkonen et al.
patent: 6180758 (2001-01-01), Chong et al.
patent: 6403306 (2002-06-01), Stephens et al.
patent: 6420169 (2002-07-01), Read et al.
patent: 6426067 (2002-07-01), Matthews et al.
patent: 6482928 (2002-11-01), Pai et al.
patent: 6540999 (2003-04-01), Harn et al.
patent: 6656472 (2003-12-01), Chong et al.
patent: 2002/0123609 (2002-09-01), Frechet et al.
patent: 2004/0022840 (2004-02-01), Nagy et al.
patent: 2004/0047866 (2004-03-01), Harn et al.
patent: 2004/0057958 (2004-03-01), Waggoner et al.
patent: 2004/0096461 (2004-05-01), Michon et al.
patent: 497525 (1992-08-01), None
patent: WO 96/40225 (1996-12-01), None
patent: WO 96/40242 (1996-12-01), None
patent: WO 98/43677 (1998-10-01), None
Chong et al, Infec. Immun., 65(12):4918-25, Dec. 1997.
Zhang et al, Cancer Res., 55:3364-3368, Aug. 1, 1995.
Paul, Immunology, Raven Press, 1993.
Lindberg et al, Infection and Immunity, 1983, 41/3:888-895.
Robbins et al, Annals NY Acad. Sci., 1995, 754:68-82.
Chong et al, Infection and Immunity, 1992, 60/11:4640-4647.
Paton, Trends in Microbiology, 1998, 6/3:85-87.
Michon et al, Vaccine, 1998, 16/18:1732-1741.
Wessels et al, J. Infectious Diseases, 1995, 171:879-884.
Porro et al, Molecular Immunology, 1986, 23/4:385-391.
Briles et al, Microbial Drug Resistance, 1997, 3/4:401-408.
Zhang et al, Infection and Immunity, 2001, 69/6:3827-3836.
Bay S. et al: “Preparation of a Multiple Antigen Glycopeptide (Mag) Carrying the TN Antigen” Journal of Peptide Research, vol. 49, No. 6, Jun. 1, 1997, pp. 620-625.
Steinhoff, M.C. et al: “A Randomized Comparison of Three Bivalent Streptococcus Pneumoniae Glycoprotein Conjugage Vaccines in Young Children: Effect of Polysaccharide Size and Linkage Characteristics”, Pediatric Infectious Disease Journal, vol. 13, No. 5, May 1, 1994, pp. 368-372.
Malcolm, A.J. “Improved Conjugate Vaccines” Journal of Cellular Biochemistry, Supplement, vol. Suppl. 17C, No. 11, Feb. 8, 1993, p. 90.
Paradiso, P.R. et al: “Glycoconjugate Vaccines: future combinations” Developments in Biological Standardization, (1996) 87 269-275 Ref: 12.
MMWR, (1994) 43:23-26.
MMWR (1989) 38:64-76.
Austrian R. (1981)Rev. Infect. Dis.3 (Suppl):S1-S17.
Dagan et al., (1992)J. Am. Med. Assoc.268:3328-3332).
H. Jennings et al, (1986), J. Immun. 127, 1011.
H. Jennings et al. J. Immunol., 1986, 137, 1708.
Peeters et al., (1991)Infect. Immun.59:3504-3510.
Paradiso et al., (1993)Vaccine Res.4:239-248.
Schneerson et al. (1980)J. expt. Med.152: 361.
Barington et al. 1993,Infect. Immun.61:432-438.
Svennerholm, 1957,Biochem. Biophys. Acta.604:24.
Walker et al. (1987),Infect. Immun.58:1184-1189.
Yother and Briles (1992),J. Bacteriol.174:601-609.
Sampson et al.,Infect. Immun.62:319-324.
Rokbi et al., (1995)FEMS Microbiol. Lett.132: 277-283.
Stimson et al., (1995),Mol. Microbiol.17:1201-1214.
McGuinness et al., (1990),J. Exp. Med.171:1871-1882.
De Velasco et al.,Infect. Immun.63:961-968.
Eby et al., (1994) In Vaccine 94:Modern Approaches to Vaccinespp. 119-124. Edited by E. Norry, F. Brown, R.M. Chanock and Ginsberg, H.S. Cold Spring Harbor, N.Y. Cold Spring Harbor Press.
Kandil et al., (1997)Glycoconjugate J.14:13-17.
Tam (1996,J. Immun. Meth.196:1732).
Ridles et al., (1983)Methods Enzymol.91: 49-60.
Sia et al, Scan. J. Immunol. 26: 683-690 author DY Sia and JL. Chou.
Wiertz et al., In Rivier, J and Marshall, G.R. (Ed.)Peptides: Chemistry, Structure and Biology,(Proceedings of the 11th American Peptide Symposium), ESCOM, Leiden, 1990, p. 371-372.
McQueen et al., (1991)Pediatr. Res.31 (part 2): Abstract 1056.
Chong Pele
Klein Michel
Lindberg Alf
Aventis Pasteur, Inc
Aventis Pasteur, Inc
Minnifield N. M.
LandOfFree
Multi-oligosaccharide glycoconjugate bacterial meningitis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multi-oligosaccharide glycoconjugate bacterial meningitis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multi-oligosaccharide glycoconjugate bacterial meningitis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3574080